On November 23, 2020 Imago BioSciences, Inc. ("Imago") a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, reported its participation in the Piper Sandler 32nd Annual Healthcare Conference to be held virtually December 1 – 3, 2020 (Press release, Imago BioSciences, NOV 23, 2020, View Source [SID1234571601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hugh Young Rienhoff, Jr. M.D., chief executive officer of Imago BioSciences, will participate in a fireside chat with Christopher Andrews. The fireside chat will be pre-recorded and available on the Piper Sandler website to registered attendees beginning on Monday, November 23, 2020 at 10:00 am ET. The Company will host the one-on-one meetings with investors on Monday, November 30, 2020, meetings can be requested exclusively via Piper Sandler.

On November 23, 2020  Crinetics Pharmaceuticals (Nasdaq: CRNX), reported that company management will participate in the following conferences in the month of December (Press release, Crinetics Pharmaceuticals, NOV 23, 2020, View Source [SID1234573405]). Please see additional details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EVERCORE ISI 3RD ANNUAL HEALTHCONX CONFERENCE
Date: Thursday, December 3rd, 2020
Time: 1:00-1:45 pm ET in Track 1
Panel: Easy Pills to Swallow: Oral Drugs for Large Endo Markets
Presenter: Dr. Scott Struthers, Founder & CEO

PIPER SANDLER’S 32ND ANNUAL HEALTHCARE CONFERENCE
Date: Tuesday – Thursday, December 1st-3rd, 2020
Time: On demand
Presenter: Dr. Scott Struthers, Founder & CEO, and Dr. Alan Krasner, Chief Medical Officer

Webcast: Pre-recorded fireside chats will be available for viewing until the 3rd here 32nd annual Piper Sandler Healthcare Conference and the Piper Sandler conference website.

On November 23, 2020 ImmunityBio, a privately-held immunotherapy company, reported the publication in Cancer Immunology, Immunotherapy of preclinical data demonstrating that ImmunityBio’s AnktivaÔ (IL-15 superagonist also known as N-803) improves interferon-gamma (IFN-g) production and killing of tumor of cells in vitro and in vivo by CD34+ progenitor-derived natural killer (NK) cells (Press release, Altor BioScience, NOV 23, 2020, View Source [SID1234571563]). Anktiva is currently being evaluated in late-stage clinical trials in combination with NantKwest’s (NASDAQ: NK) NK cell therapies for multiple indications including metastatic pancreatic cancer, triple negative breast cancer (TNBC), bladder cancer and lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"While allogeneic NK cell therapy is a promising and potentially paradigm-shifting approach for cancer immunotherapy, there are still considerable challenges remaining in the field," said Patrick Soon-Shiong, M.D., Chairman and CEO of ImmunityBio. "One way to boost NK cell function is through the use of IL-15, however, its short in vivo half-life limits its utility in the clinic. Anktiva was developed to overcome the limitations of IL-15 to fully unleash the potential of NK cell immunotherapy. These preclinical data are an important step forward in demonstrating the potential of Anktiva to boost NK cell functionality by increasing the production of key cytokines and improving killing properties across diverse in vitro and in vivo cancer models. Importantly, these data provide validating proof-of-mechanism that support the encouraging clinical data observed to date when combining Anktiva with NantKwest’s NK cell therapies across a range of challenging solid tumors with poor prognoses. We look forward to the continued evaluation of Anktiva as a promising IL-15 superagonist, which may be broadly applied to improve NK cell-based immunotherapies."

Key findings from the study performed under the guidance of Prof. Harry Dolstra at the Radboud Institute for Molecular Life Sciences in The Netherlands, reported in the publication titled, "IL‐15 superagonist N‐803 improves IFN-g production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‐derived NK cells" include:

Anktiva induces HPC-NK cell proliferation in a dose-dependent manner;
Treatment with Anktiva increases IFN-g production in CD34+ hematopoietic progenitor-derived NK cells (HPC-NK) stimulated with leukemia cells lines and improves killing of primary AML samples from patients;
Anktiva improves serial killing properties of HPC-NK cells against leukemia as measured by live cell imaging with single cell resolution;
Anktiva increases CXCL10 production and improves long-term HPC-NK cell-mediated killing in ovarian cancer spheroids, an ovarian cancer model which mimics three-dimensional growth of ovarian cancer in vivo;
HPC-NK cells combined with Anktiva and nanogam (human immunoglobulins) show anti-tumor effects in a human ovarian cancer mouse model;
Together, these data point to the clear potential of AnktivaÔ to improve efficacy of NK cell-based immunotherapies by promoting HPC-NK cell expansion and functionality.

On November 23, 2020 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported financial results for its fiscal year ended September 30, 2020 (Press release, Arrowhead Research Corporation, NOV 23, 2020, View Source [SID1234571582]). The company is hosting a conference call at 4:30 p.m. EST to discuss results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company’s website at View Source For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8492751.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8492751.

Selected Recent Events

Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, now called olpasiran, in a Phase 2 clinical study
Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis
Initiated a Phase 1b study of ARO-HIF2, the company’s first tumor targeted investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma
Presented new clinical data from Phase 1/2 studies of both wholly owned cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology and the American Heart Association meetings, and subsequently hosted key opinion leader webinars to discuss the data and plans for future development of the product candidates
Presented new clinical data at The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) on ARO-AAT, Arrowhead’s candidate against liver disease associated with alpha-1 antitrypsin deficiency, showing that ARO-AAT strongly reduced the production of mutant Z-AAT protein and led to improvements in multiple biomarkers of alpha-1 liver disease
Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, which includes $300 million upfront, $740 million in potential milestone payments, a 50/50 profit sharing agreement in the U.S., and 20-25% royalty on sales outside the U.S.

On November 23, 2020 Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology, and Tempus, a leader in artificial intelligence and precision medicine, reported their collaboration to accelerate patient enrollment for Novellus’ next generation BRAF inhibitor program (Press release, Novellus, NOV 23, 2020, View Source [SID1234571604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas. Novellus will participate in Tempus’s TIME Trial Network, and the companies will work together to identify relevant patients to accelerate patient enrollment.

"The collaboration with Tempus will enable us to accelerate the enrollment of patients in our BRAF trial, by precisely identifying potential candidates and opening sites wherever the patients are found" said Michael Vidne, Chief Executive Officer of Novellus.

"The TIME Trial Program has achieved an unparalleled scale thus far, with over 50 provider networks and 2,500 oncologists included in its network," said Kim Blackwell, Chief Medical Officer of Tempus. "We’re excited to collaborate with Novellus, to further our mission to increase trial participation, and to ultimately bring the right treatment to the right patients at the right time."